Aims Our goal was to analyse whether truncated peroxisome proliferator-activated receptor a (PPARa) overexpression induces apoptosis of cardiomyocytes.
Introduction
Several studies have demonstrated the implication of cardiomyocyte apoptosis in the development of heart failure (HF). In fact, increased cardiomyocyte apoptosis has been shown in spontaneously hypertensive rats (SHR) with left ventricular hypertrophy (LVH) and HF compared with SHR with LVH, 1 and in hypertensive patients with chronic HF and LVH compared with hypertensives with LVH and normal cardiac function.
2,3
The peroxisome proliferator-activated repector a (PPARa) is a transcription factor that has been shown to be involved in the development of LVH and the transition from LVH to HF. 4 Two isoforms of PPARa have been described in the human heart: a native isoform that gives rise to an active protein of 53 kDa and a truncated isoform that lacks the exon 6 and gives rise to a protein of 30 kDa. 5, 6 In vitro experiments performed in human hepatic cells and in cardiomyocytes demonstrated that truncated PPARa has a repressive action on native PPARa activity, probably through competition for essential coactivators. 6, 7 This repressive activity is not specific for native PPARa, because truncated PPARa is also a potent repressor of the activity of nuclear receptors like PPARg, related orphan receptor-a (RORa), and glucocorticoid receptor-a (GRa). 6 Recently, our group demonstrated that, although a decrease in native PPARa expression was associated with the development of LVH in hypertensive patients, overexpression of truncated PPARa was associated with the transition from LVH to HF in hypertensives. 2 The excess of truncated PPARa protein was associated with a decrease in the ejection fraction and the dilatation of the left ventricular chamber in these patients. Moreover, we observed a direct association of truncated PPARa protein with cardiomyocyte apoptosis in hypertensive patients. 2 It is interesting to note that these associations were independent of the expression of native PPARa. 2 We thus have hypothesized that an increase of truncated PPARa may induce cardiomyocyte apoptosis. To test this hypothesis, the present study was designed to analyse different hallmarks of cellular apoptosis in HL-1 cardiomyocytes transfected with human truncated PPARa. In addition, the effects of transfection with truncated PPARa on the expression of apoptosis regulatory proteins of the Bcl-2 family were investigated in HL-1 cells. As the cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB)/CREB binding protein (CBP) complex may inhibit cardiomyocyte apoptosis through induction of Bcl-2, 8, 9 experiments were also performed to assess whether truncated PPARa interacts with the above complex.
Methods

Construction of recombinant vectors
To obtain the cDNA of human truncated PPARa, a reverse transcription polymerase chain reaction (RT-PCR) was performed. Reverse transcription was performed with 5 mg of total RNA from human library (Human Heart Total RNA, Ambion, TX, USA) using the Superscript III Reverse Transcriptase (Invitrogen, Barcelona, Spain). Two primers were designed to amplify the cDNA with the following sequences: (i) 5 0 -CACCATGGT GGACACGGAAAG CCCACT-3 0 corresponding to sequences 1-23 of the human truncated PPARa cDNA and (ii) 5 0 -TCATGTATGACAAAAGGCGTT GTGTGACAT-3 0 corresponding to sequences 495-525 of the human truncated PPARa cDNA. Taq Platinum High Fidelity DNA polymerase (Invitrogen, Barcelona, Spain) was used in the PCR to minimize the probability of DNA mutations. Amplified products were separated by electrophoresis, showing one band of about 530 bp, the expected size for truncated PPARa. PCR products were purified, cloned into a pcDNA3.1/V5-His & TOPO w vector and transformed into TOP10 Escherichia coli cells. The recombinant vector obtained from these cells was sequenced using the dideoxy chain-termination method, 10 showing the predicted sequence of human truncated PPARa. 6 To construct a recombinant vector for human CREB, an RT-PCR was performed as previously described for truncated PPARa. The primers used for CREB amplification have the following sequences: (i) CREB forward: 5 0 -GACGGAGGAGCTTGTACCACCGGTAACTAA-3 0 and (ii) CREB reverse: 5 0 -TTCAGGTTGTGGCCAAGCCAGTCC-3 0 . CREB human cDNA was cloned, transformed, and sequenced as previously described.
Transfection of human truncated PPARa
HL-1 murine cells were grown in Claycomb Medium supplemented with 10% foetal bovine serum, 1% penicillin/streptomycin, 1% norepinephrine, and 1% L-glutamine, in a 5% CO 2 -humidified atmosphere at 378C.
All transfections were performed with a mixture of truncated PPARa expression vector (60, 200, and 400 ng) and b-galactosidase expression vector as control for transfection efficiency (500 ng). All samples were complemented to an equal amount of transfected DNA using the pcDNA3.1/V5-His & TOPO w empty vector. Cells were transfected at 40-50% confluence using the Lipofectin reagent (Invitrogen, Barcelona, Spain) and OPTIMEM (GIBCO, Barcelona, Spain) serum-free medium. After 5 h of incubation with the transfection mixture, the medium was replaced with supplemented Claycomb Medium and cells were incubated for 24 h.
After the incubation for 24 h, HL-1-transfected cells were washed with phosphate-buffered saline (PBS) (Gibco, Barcelona, Spain), tripsinized, and collected by centrifugation at 200 g for 5 min at 48C. HL-1 pellet was resuspended in PBS and two flasks of cells were counted in a Neubauer counting chamber, to obtain an approximation of the HL-1 cell number.
Detection of truncated PPARa in HL-1-transfected cells 2.3.1 Detection of truncated PPARa mRNA
The RNA of the transfected cells was isolated with TRIzol (Invitrogen, Barcelona, Spain) and subsequently purified using QIAGEŃs RNeasy Total RNA Isolation Kit according to the manufacturer's conditions. The presence of truncated PPARa mRNA in transfected cells was demonstrated using RT-PCR. The reverse transcription was performed with 1 mg of total RNA and the cDNA obtained was amplified by real-time PCR using specific primers flanking exon 6 of human PPARa cDNA with the following sequences: (i) 5
0 -TGTCGGGATGTCACACAACG-3 0 for the forward primer and (ii) 5 0 -GCCATACACAGTGTCTCCATATCAT-3 0 for the reverse primer.
Detection of truncated PPARa protein
The truncated PPARa protein expression was demonstrated in HL-1 transfected cells by western blot. Protein was extracted in lysis buffer (7 mol/L urea, 2 mol/L thiourea, 4% Chaps, 1% dithiothreitol) and aliquots containing 10 mg of total protein were diluted in 4Â sample buffer (40% b-mercaptoethanol, 8% sodium dodecyl sulphate, 40% glycerol, 0.025% bromophenol blue, and 0.25 mmol/L Tris, pH 6.4), separated by electrophoresis on 10% polyacrylamide gel and transferred onto nitrocellulose membranes. Specific rabbit polyclonal antibody (Cayman Chemical, Ann Arbor, MI, USA.) against the aminoterminal portion of PPARa, common to both isoforms of PPARa, was incubated at a dilution of 1:500. Bands were detected by incubation with the peroxidase-conjugated anti-rabbit IgG (Amersham, Barcelona, Spain) at a dilution of 1:5000. Both PPARa isoforms were visualized with the ECL-Plus chemiluminescence system (Amersham, Barcelona, Spain) and autoradiograms were analysed using an automatic densitometer (Quantity One, Bio-Rad, Barcelona, Spain).
Analysis of apoptotic hallmarks
To assess whether truncated PPARa overexpression is associated with cardiomyocyte apoptosis, a number of apoptotic hallmarks were analysed in HL-1-transfected and in HL-1 non-transfected cells that served as controls. In each experiment, b-galactosidase activity was analysed in the same number of cells as control for transfection efficiency using fluorescein-b-D-galactopyranoside in a flow cytometer (FAC Scan, Becton Dickinson, Madrid, Spain) using the Cell Quest program. All analysed parameters were normalized to b-galactosidase activity.
Depolarization of mitochondrial membrane
To analyse the HL-1 mitochondrial membrane potential, we used the JC-1 dye (Molecular probes, Invitrogen, Barcelona, Spain) which shifts the fluorescence emission from red (approximately 590 nm) to green (approximately 527 nm) when the mitochondrial membrane is depolarized. 11 Therefore, the ratio of the 527/590 nm absorbance, analysed in a flow cytometer, indicates the mitochondrial membrane depolarization.
Data are expressed as fold change in the number of cells with mitochondrial membrane depolarization with respect to non-transfected HL-1 cells.
Caspase-3 activation
To analyse the activation of caspase-3 in HL-1-transfected cells, an electrophoresis on 12% polyacrylamide gel was performed as previously described, and the proteins were transferred onto nitrocellulose membranes. The membranes were excised to detect the procaspase and the active caspase separately, and incubated overnight at 48C with a caspase-3-specific rabbit polyclonal antibody (Cell Signaling, Danvers, MA, USA.) at a dilution of 1:1000 to analyse the inactive procaspase, and at 1:500 to analyse the 17-21 kDa active fragments. These fragments were detected by incubation for 1 h at room temperature with a peroxidaseconjugated anti-rabbit IgG (Amersham, Barcelona, Spain) at a dilution of 1:2500. The blots were reprobed with a monoclonal b-actin antibody (Sigma, Madrid, Spain) as a control for loading. The bands were visualized and analysed as previously described.
As the ratio between the active fragments and the inactive procaspase-3 is an indicator of caspase-3 activation, 12 data are expressed as the ratio of 17-21 kDa active caspase-3/35 kDa procaspase-3.
Phosphatidylserine externalization
To analyse the cardiomyocyte phosphatidylserine (PS) exposition, the 'Annexin A5-FITC' Kit was employed (Pharmatarget, Maastricht, Netherlands). In this method, the annexin A5 conjugated with fluorescein isothiocyanate (FITC) fluorochrome binds to PS exposed on the plasma membrane. Cellular fluorescence was determined by flow cytometry analysis. 
DNA fragmentation
The Apo ssDNA Kit (Bachem, San Carlos, CA, USA.) can detect DNA damage in apoptotic cells using specific antibodies against singlestranded DNA (ssDNA). 
Viability assay in HL-1-transfected cells
To analyse the toxicity of truncated PPARa in HL-1-transfected cells, propidium iodide viability staining assay was performed. The fluorescence of this reagent was analysed in a flow cytometer.
Data are expressed as fold change in the number of propidium iodide-positive cells with respect to non-transfected HL-1 cells.
2.6 Analysis of the apoptotic regulatory proteins Bcl-2, Bax, and cytochrome c
To analyse the expression of Bax and Bcl-2 in HL-1-transfected cells, an electrophoresis on 12% polyacrylamide gel was performed and proteins were transferred onto nitrocellulose membranes as previously described. To identify the presence of Bax and Bcl-2 proteins, a Bax-specific rabbit polyclonal antibody at a dilution of 1:500 and a Bcl-2-specific mouse polyclonal antibody at a dilution of 1:500 were used (Santa Cruz Biotechnology, Heidelberg, Germany). The membranes were incubated with both antibodies overnight at 48C and 1 h at room temperature with a peroxidase-conjugated antirabbit IgG at a dilution of 1:2500 (Amersham, Barcelona, Spain) and with a peroxidase-conjugated anti-mouse IgG at a dilution of 1:2500 (Amersham, Barcelona, Spain) for Bax and Bcl-2 detection, respectively. The blots were reprobed with a monoclonal b-actin antibody (Sigma, Madrid, Spain) as a control for loading. The bands were visualized and analysed as previously described.
To analyse if the effect of truncated PPARa on Bax and/or Bcl-2 protein expression could induce the release of cytochrome c from mitochondria to cytosol, subcellular fractionation of HL-1 lysates was realized, following the methodology employed by Nakagawa et al., 15 with some modifications. In these cellular fractions, the proteins were separated on 12% polyacrylamide gel and transferred onto nitrocellulose membranes as previously described. A polyclonal antibody against cytochrome c at a dilution of 1:1000 (Cell Signaling, Danvers, MA, USA.) and a conjugated anti-rabbit IgG at a dilution of 1:2500 (Amersham, Barcelona, Spain) were used to measure the cytochrome c protein expression. The bands were visualized and analysed as previously described.
To explore whether truncated PPARa can modify the antiapoptotic pathway CREB-Bcl-2, additional experiments were performed measuring Bcl-2 expression in HL-1 cells co-transfected with 400 ng of truncated PPARa, 1 mg of human CREB, and 400 ng of the human coactivator CBP. These co-transfections were performed in the same conditions previously described for truncated PPARa transfections in HL-1 cardiomyocytes. In one group of HL-1 cells truncated PPARa was co-transfected with CREB, and in other group of HL-1 cells truncated PPARa was co-transfected with both CREB and CBP.
Data are expressed as arbitrary densitometric units (A.D.U.) relative to b-actin expression.
Statistical analysis
To analyse any tendency in the parameters measured, the linear test for trend was used. Differences between two samples were tested by a Student's t-test for unpaired data once normality was demonstrated (Shapiro-Wilks test); otherwise, a non-parametric test (Mann-Whitney U test) was used. The correlation between continuously distributed variables was tested by univariate regression analysis. The analysis was performed using the SPSS program (13.0 version). Values are expressed as mean+SEM. A value of P , 0.05 was considered statistically significant.
Results
Expression of truncated PPARa in transfected HL-1 cardiomyocytes
To analyse the presence of truncated PPARa mRNA in HL-1-transfected cells, an RT-PCR was performed with specific primers flanking exon 6 of human PPARa cDNA. PCR products were separated by electrophoresis, showing a single band of about 60 bp, the expected size for the truncated PPARa fragment, only in HL-1-transfected cells ( Figure 1A) . As shown in Figure 1B , a single band of 53 kDa, which corresponds to endogenous native PPARa, can be observed in both non-transfected and transfected HL-1 cells. However, a band of 30 kDa, specific for truncated PPARa, can be detected only in transfected HL-1 cells. The expression of truncated PPARa was thus demonstrated both at the mRNA level and at the protein level in transfected cells, these results demonstrating that the transfection experiments were successful. Transfection efficiency in HL-1 cardiomyocytes was about 15-20%.
Induction of apoptosis by truncated PPARa transfection in HL-1 cardiomyocytes 3.2.1 Depolarization of the mitochondrial membrane
We observed a progressive depolarization of the mitochondrial membrane (P for trend ,0.05) in association with the progressive increase in the levels of truncated PPARa transfected into HL-1 cells (Figure 2 ).
Activation of caspase-3
A dose-dependent increment in caspase-3 activation (P for trend ,0.05) was observed in HL-1-transfected cells (Figure 3) .
Phosphatidylserine externalization
Transfection of HL-1 with increasing amounts of truncated PPARa induced the progressive increment (P for trend ,0.05) in PS externalization in HL-1 cardiomyocytes (Figure 4 ).
DNA fragmentation
As shown in Figure 5 , truncated PPARa transfection induced DNA fragmentation in HL-1 cells (P for trend ,0.05).
Induction of cell death by truncated PPARa transfection in HL-1 cardiomyocytes
Truncated PPARa induced a dose-dependent increase (P for trend ,0.01) in cell death in HL-1 cardiomyocytes (Figure 6 ).
Changes in Bcl-2 protein and cytochrome c release by truncated PPARa transfection in HL-1 cardiomyocytes
The expression of the antiapoptotic protein Bcl-2 was reduced (P , 0.05) in HL-1 cells transfected with 400 ng of truncated PPARa when compared with non-transfected cells (Figure 7) . No differences were observed in Bax expression between non-transfected HL-1 cells and HL-1 cells transfected with 400 ng of truncated PPARa (data not shown). Of interest, Bcl-2 protein expression was inversely correlated with mitochondrial membrane depolarization (r ¼ 20.573, P , 0.001), caspase-3 activation (r ¼ 20.543, P , 0.01), and PS externalization (r ¼ 20.332, P , 0.05) in transfected HL-1 cells. Moreover, truncated PPARa overexpression induced the release of cytochrome c from mitochondria to cytosol, increasing the ratio of cytosolic/mitochondrial cytochrome c (P , 0.05) in HL-1 transfected vs. non-transfected cells.
Interestingly, the ability of truncated PPARa to inhibit Bcl-2 expression was abolished when HL-1 cells were co-transfected with CREB plus CBP (Figure 7) . 
Discussion
The main finding of this study is that human truncated PPARa overexpression is associated with the induction of apoptosis in HL-1 cardiomyocytes. In fact, truncated PPARa overexpression resulted in depolarization of mitochondrial membrane, activation of caspase-3, PS externalization, DNA fragmentation, and cardiomyocyte death.
Stimulation of cardiomyocyte apoptosis may compromise cardiac function through the decrease of the contractility mass because of the loss of cardiomyocytes and the dilatation of the left ventricle because of the side-to-side slippage of remaining cardiomyocytes. 2, 16, 17 The stimulation of apoptosis may also impair the functionality of viable cardiomyocytes. 18 In fact, caspase-3 activation has been shown to lead to cleavage of myofilaments, disruption of sarcomeric structure, and an alteration of contractile force in cardiomyocytes. 19, 20 Moreover, the release of cytochrome c from mitochondria to cytosol, a protein involved in ATP production, because of the depolarization of the mitochondrial membrane, may therefore interfere with energy production and lead to systolic dysfunction. 21, 22 Thus, truncated PPARa emerges as a potential factor involved in the transition from LVH to HF in hypertension through cardiomyocyte apoptosis.
Another finding of this study is that truncated PPARa overexpression is associated with Bcl-2 downregulation in HL-1 cardiomyocytes. As no changes in Bax expression were observed in transfected cells, it can be hypothesized that the relative deficiency of Bcl-2 may contribute to mitochondrial membrane depolarization and the release of apoptogenic molecules like cytochrome c from the mitochondria to the cytosol, inducing the activation of caspase-3 and, consequently, the externalization of PS and the fragmentation of DNA. In support of this possibility, we found that Bcl-2 downregulation was associated with the depolarization of the mitochondrial membrane, caspase-3 activation, and PS externalization in transfected cells, and that truncated PPARa overexpression induces the release of cytochrome c from mitochondria to cytosol.
Our observation that the inhibitory effect of truncated PPARa on Bcl-2 expression is reversed by overexpression of both CREB and CBP suggests that truncated PPARa may downregulate the CREB-Bcl-2 pathway through sequestration of CBP. In this regard, it has been reported that truncated PPARa inhibits the trancriptional activity of native PPARa through competition for CBP. 6 In summary, we have demonstrated for the first time that truncated PPARa overexpression induces apoptosis in HL-1 cardiomyocytes, probably through downregulation of the antiapoptotic protein Bcl-2. It is tempting to speculate that sequestration of CBP could be a mechanism by which truncated PPARa might inhibit the CREB-Bcl-2 pathway. Nevertheless, additional proapoptotic mechanisms cannot be excluded. Although in vivo experiments are necessary to confirm the proapoptotic effect of truncated PPARa overexpression in the heart, findings here reported add mechanistic support to our previous report 2 describing an independent association between truncated PPARa overexpression and increased cardiomyocyte apoptosis in the myocardium of HF patients. Thus, truncated PPARa may be a target for strategies aimed to inhibit apoptotic death of cardiomyocytes in the failing human heart.
